Biomarker Lens

Biomarkers · Chemical

Ganglioside GM-1 Antibodies IgG

What it measures

Also listed as
Ganglioside GM-1 Antibodies (IgG
Tests in the graph that measure it
4

A plain-language description with its source has not been added for this biomarker yet. What the laboratories say about the tests that measure it is below.

Tests that measure Ganglioside GM-1 Antibodies IgG

Motor Neuropathy Complete Antibody Panel

Laboratory
Quest Diagnostics
Test code
90137
Specimen
Serum
Fasting
Required

What the laboratory says this test is for

The panel includes ganglioside antibodies associated with motor neuropathies. Many of the anti-ganglioside antibodies associated with chronic immune neuropathies are monoclonal IgM antibodies. An evaluation for monoclonal gammopathy should be performed in this setting.

Quest Diagnostics test directory, test code 90137

Sensory-Motor Neuropathy Antibody Panel Ganglioside

Laboratory
Quest Diagnostics
Test code
90129
Specimen
Serum
Fasting
Required

What the laboratory says this test is for

The presence of antibodies to the gangliosides GM1, Asialo-GM1, GD1a and GD1b has been associated with motor and sensorimotor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases of chronic immune neuropathies, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers. Polyclonal GQ1b IgG antibody can serve as an aid in the diagnosis of acute ataxia neuropathy with ophthalmoplegia or of Miller-Fisher Syndrome.

Quest Diagnostics test directory, test code 90129

Sensory-Motor Neuropathy Complete Antibody Panel

Laboratory
Quest Diagnostics
Test code
90136
Specimen
Serum
Fasting
Required

What the laboratory says this test is for

Sensory-motor neuropathies may occur by various mechanisms. These include development of autoantibodies to neuronal structures such as myelin associated glycoprotein (MAG) antibody, Hu antibody, and the ganglioside antibodies. Sensory-motor neuropathies may also occur via antibody cross-reactivity or local immune complex deposition as seen in autoimmune disease with primarily non-neuronal targets including Sjogren's syndrome (SSA/SSB), systemic lupus erythematosus and related conditions (ANA IFA), celiac disease (tTG antibody), vasculitis (ANCA), and immune complex deposition (cryoglobulins, rheumatoid factor). Motor-sensory neuropathy may be associated with monoclonal gammopathy (serum immunofixation and serum immunoglobulins).

Quest Diagnostics test directory, test code 90136

Ganglioside Antibody Panel 6

Laboratory
Quest Diagnostics
Test code
90131
Specimen
Serum
Fasting
Required

What the laboratory says this test is for

The presence of antibodies to the gangliosides GM1, Asialo-GM1, and GD1a has been associated with motor neuropathies. High titers of antibody to GM1 are most typical of multifocal motor neuropathy; however, antibodies to other gangliosides are often present. In most cases, anti-ganglioside antibodies are IgM class. IgG antibodies have been reported less often, generally associated with acute conditions. Many reports have found increased anti-asialo-GM1 antibody titers in patients with multifocal motor neuropathy, lower motor neuron disease, or motor neuropathy with or without multifocal block, Guillain-Barré Syndrome, and amyotrophic lateral sclerosis. There may be a relationship between titers of asialo-GM1 antibodies and clinical status in individual patients. In some lower motor neuron disorders, improvement in strength has occurred after therapeutic reduction in anti-asialo-GM1 antibody titers.

Quest Diagnostics test directory, test code 90131

About this page

Everything above is drawn from the named sources and shown as they published it. Reference ranges belong to the laboratory that issued them and the population it named; they are not a universal normal. This page describes the biomarker in general and does not interpret anyone's result. For your own numbers, talk to a clinician, or use Aumnivida, which reads the same graph next to your records.

Found an error? Write to hello@biomarkerlens.com with the page link and the source that contradicts it.